Summary
Danaher Corporation's Q2 2011 10-Q filing reveals a period of significant transformation, primarily driven by the monumental acquisition of Beckman Coulter for approximately $5.5 billion. This acquisition, completed at the end of June 2011, was financed through a combination of cash, equity, and debt offerings, substantially increasing the company's assets, goodwill, and long-term debt. The deal significantly bolsters Danaher's Life Sciences & Diagnostics segment and is expected to drive future growth and cost synergies. Financially, the company reported strong sales growth across most segments, aided by existing business performance and favorable currency translations. However, the report also highlights the impact of acquisition-related costs, particularly for Beckman Coulter, which affected short-term earnings and operating profit margins. While the company successfully divested its Pacific Scientific Aerospace business for a notable gain, the overall financial narrative for this quarter is dominated by the strategic integration of Beckman Coulter and its implications for future financial performance.
Financial Highlights
51 data points| Revenue | $3.64B |
| Cost of Revenue | $2.26B |
| Gross Profit | $1.92B |
| R&D Expenses | $287.51M |
| SG&A Expenses | $1.27B |
| Operating Income | $610.00M |
| Interest Expense | $42.36M |
| Net Income | $648.80M |
| EPS (Basic) | $0.97 |
| EPS (Diluted) | $0.94 |
| Shares Outstanding (Basic) | 687.26M |
| Shares Outstanding (Diluted) | 710.40M |
Key Highlights
- 1Completed the transformative acquisition of Beckman Coulter, Inc. for approximately $5.5 billion in late June 2011.
- 2Reported significant sales growth across most business segments, with notable strength in China and emerging markets.
- 3Implemented a new reporting structure with five distinct business segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies.
- 4Divested the Pacific Scientific Aerospace business, resulting in an after-tax gain of approximately $202 million.
- 5Net cash used in investing activities surged to $5.5 billion, primarily due to the Beckman Coulter acquisition.
- 6Financed the Beckman Coulter acquisition through a combination of cash ($2.3 billion), common stock offering ($966 million), senior unsecured notes ($1.8 billion), and commercial paper.
- 7Increased long-term debt significantly due to debt assumed with the Beckman Coulter acquisition and new debt issuances, reaching $6.5 billion from $2.8 billion.
- 8Total assets grew substantially to $31.5 billion from $22.2 billion, largely driven by the Beckman Coulter acquisition and associated goodwill.